

AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF THE CLAIMS

1. (Previously Presented) A method of topically treating efflorescence diseases of the skin and mucous membrane caused by herpes simplex virae, said method comprising the administration of a pharmaceutical preparation to the area to be treated of the alkali and/or alkaline earth salts of tosylchloramide.

Claim 2 (Cancelled)

3. (Cancel) The method of Claim 1, characterized in that the diseases result in efflorescences.

Claim 4 (Cancelled)

Claim 5 (Cancelled)

6. (Previously Presented) The method of Claim 1, characterized in that the diseases affect:

- a) the lid, conjunctiva or cornea of the eye;
- b) the exterior of the ear;
- c) the nasal cavity;
- d) the lips and mucous membranes of the mouth and/or the tongue;
- e) the vulva and/or vagina;
- f) the penis;
- g) the anus;
- h) the nail;
- i) the hair follicles and/or the sebaceous glands; and/or
- j) the hands and feet.

7. (Previously Presented) The method of Claim 1, wherein said tosylchloramide salt(s), are present in an employed base in an amount of approximately 0.1 to 20% by weight.
8. (Previously Presented) The method of Claim 1, wherein sodium tosylchloramide salt is employed.
9. (Previously Presented) The method of Claim 7, wherein said base constitutes a liquid, semi-solid or solid, water-containing or water-free galenic preparation.
10. (Previously Presented) The method of Claim 9, wherein said base constitutes an ointment, a gel, a cream, a paste, a suppository, such as a vaginal suppository, an adhesive bandage, a tablet, such an effervescent or vaginal tablet, or a capsule, a stick, a pulverized substance, a powder, a solution, an aerosol, a two-compartment system or a suspension, such as a shake mixture/dry suspension.
11. (Previously Presented) The method of Claim 9, wherein said base constitutes a dosed aerosol or a dosed solution.
12. (Previously Presented) The method of Claim 9, wherein said base constitutes a bath water additive.
13. (Previously Presented) The method of Claim 9, wherein said base is an O/W- or a W/O-emulsion ointment.
14. (Previously Presented) The method of Claim 7, wherein said base is a cortisone-containing preparation.
15. (Previously Presented) The method of Claim 9, wherein said base is a gel comprising said tosylchloramide salt(s), in an amount of approximately 0.1 to 5% by

weight.

16. (Previously Presented) The method of Claim 9, wherein a bath water additive is employed in form of pulverized substance or bath salt tablet or effervescent tablet, which is applied in water in a concentration of approximately 0.1 to 1% by weight.

17. (Previously Presented) The method of Claim 1, wherein said tosylchloramide salt(s), are present in an employed base in an amount of approximately 5 to 15% by weight.

18. (Previously Presented) The method of Claim 1, wherein said tosylchloramide salt(s), are present in an employed base in an amount of approximately 8 to 12% by weight.

19. (Previously Presented) The method of Claim 9, wherein the base is a gel, in which are present said tosylchloramide salt(s), in an amount of approximately 0.1 to 2% by weight.

20. (Previously Presented) The method of claim 1, further comprising a treatment schedule including an application duration from about 2 to about 20 days and an application frequency from about 1 to about 4 times per day.

21. (Previously Presented) The method of claim 1, further comprising a treatment schedule including an application duration from about 2 to about 6 days and an application frequency from about 1 to about 3 times per day.

Claims 22. – 33 (Cancelled)

34. (Previously Presented) A method of topically treating efflorescence diseases

of the skin and mucous membranes caused by the herpes simplex virae comprising:

application of a pharmaceutically prepared medicament, to the area to be treated, having a salt of tosylchloramide selected from the group consisting of alkali salts, alkaline earth salts and mixtures thereof in an employed base in an amount of approximately 0.1 to 20% by weight.

35. (Previously Presented) The method of claim 34, wherein said base constitutes a liquid, semi-solid or solid, water-containing or water-free galenic preparation.

36. (Previously Presented) The method of claim 35, wherein said base constitutes an ointment, a gel, a cream, a paste, a suppository, such as a vaginal suppository, an adhesive bandage, a tablet, such an effervescent or vaginal tablet, or a capsule, a stick, a pulverized substance, a powder, a solution, an aerosol, a two-compartment system or a suspension, such as a shake mixture/dry suspension.

37. (Previously Presented) The method of claim 35, wherein said base constitutes a dosed aerosol or a dosed solution.

38. (Previously Presented) The method of claim 35, wherein said base constitutes a bath water additive.

39. (Previously Presented) The method of claim 35, wherein said base is an O/W- or a W/O-emulsion ointment.

40. (Previously Presented) The method of claim 34, wherein said base is a cortisone-containing preparation, containing said tosylchloramide salt(s), in an amount of approximately 0.1 to 20% by weight.

41. (Previously Presented) The method of claim 35, wherein said base is a gel comprising said tosylchloramide salt(s), in an amount of approximately 0.1 to 5% by

weight.

42. (Previously Presented) The method of claim 35, wherein the bath water additive is employed in form of pulverized substance or bath salt tablet or effervescent tablet, which is applied in water in a concentration of approximately 0.1 to 1% by weight.

43. (Previously Presented) The method of claim 34, wherein said tosylchloramide salt(s), are present in an employed base in an amount of approximately 5 to 15% by weight.

44. (Previously Presented) The method of claim 34, wherein said tosylchloramide salt(s), are present in an employed base in an amount of approximately 8 to 12% by weight.

45. (Previously Presented) The method of claim 35, wherein the base is a gel, in which are present said tosylchloramide salt(s), in an amount of approximately 0.1 to 2% by weight.

46. (Currently Amended) A method of topically treating efflorescence diseases of the skin and mucous membrane caused by herpes simplex virae, said method comprising:
applying a pharmaceutical preparation to the area to be treated;
wherein said pharmaceutical preparation including comprises alkali and/or alkaline earth salts of tosylchloramide, and wherein said tosylchloramide salts are present in an employed base in an amount of approximately 0.1 to 20% by weight; and, applying said preparation comprises a treatment schedule including an application duration from about 2 to about 20 days and an application frequency from about 1 to about 4 times per day.

47. (Previously Presented) The method of claim 46, wherein the base constitutes a liquid, semi-solid or solid, water-containing or water-free galenic preparation.